PROTALIX BIOTHERAPEUTICS INC(NYSEARCA:PLX) stock Fundamental Analysis

Fundamental Rating

PLX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. PLX has only an average score on both its financial health and profitability. PLX is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

PLX had positive earnings in the past year.

In the past year PLX has reported a negative cash flow from operations.

In multiple years PLX reported negative net income over the last 5 years.

In the past 5 years PLX reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of PLX (5.29%) is better than 92.87% of its industry peers.

PLX has a better Return On Equity (8.64%) than 93.40% of its industry peers.

The Return On Invested Capital of PLX (7.82%) is better than 93.94% of its industry peers.

		Industry Rank	Sector Rank
ROA	5.29%
ROE	8.64%
ROIC	7.82%

ROA(3y)-4.31%

ROA(5y)-11.99%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin of PLX (6.54%) is better than 91.98% of its industry peers.

With an excellent Operating Margin value of 7.74%, PLX belongs to the best of the industry, outperforming 93.40% of the companies in the same industry.

With a decent Gross Margin value of 49.97%, PLX is doing good in the industry, outperforming 76.11% of the companies in the same industry.

PLX's Gross Margin has declined in the last couple of years.

		Industry Rank	Sector Rank
OM	7.74%
PM (TTM)	6.54%
GM	49.97%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.72%

GM growth 5Y-7.42%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PLX is destroying value.

The number of shares outstanding for PLX has been increased compared to 1 year ago.

The number of shares outstanding for PLX has been increased compared to 5 years ago.

There is no outstanding debt for PLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

PLX has an Altman-Z score of -2.94. This is a bad value and indicates that PLX is not financially healthy and even has some risk of bankruptcy.

PLX has a Altman-Z score (-2.94) which is in line with its industry peers.

There is no outstanding debt for PLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2.94

ROIC/WACC0.74

WACC10.56%

2.3 Liquidity

PLX has a Current Ratio of 2.49. This indicates that PLX is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of PLX (2.49) is worse than 70.94% of its industry peers.

PLX has a Quick Ratio of 1.69. This is a normal value and indicates that PLX is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 1.69, PLX is doing worse than 79.32% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.49
Quick Ratio	1.69

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PLX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.00%.

The Revenue has been growing slightly by 0.18% in the past year.

The Revenue has been decreasing by -0.48% on average over the past years.

EPS 1Y (TTM)0%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%16.67%

Revenue 1Y (TTM)0.18%

Revenue growth 3Y11.67%

Revenue growth 5Y-0.48%

Sales Q2Q%169.6%

3.2 Future

The Earnings Per Share is expected to grow by 431.79% on average over the next years. This is a very strong growth

PLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 59.52% yearly.

EPS Next Y943.67%

EPS Next 2Y431.79%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year61.73%

Revenue Next 2Y59.52%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 40.50, which means the current valuation is very expensive for PLX.

92.51% of the companies in the same industry are more expensive than PLX, based on the Price/Earnings ratio.

PLX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.82.

The Price/Forward Earnings ratio is 1.91, which indicates a rather cheap valuation of PLX.

98.93% of the companies in the same industry are more expensive than PLX, based on the Price/Forward Earnings ratio.

PLX is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.76, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	40.5
Fwd PE	1.91

4.2 Price Multiples

PLX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PLX is cheaper than 94.47% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	18.35

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

PLX's earnings are expected to grow with 431.79% in the coming years. This may justify a more expensive valuation.

PEG (NY)0.04

PEG (5Y)N/A

EPS Next 2Y431.79%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PLX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROTALIX BIOTHERAPEUTICS INC

NYSEARCA:PLX (5/23/2025, 8:47:00 PM)

After market: 1.62 0 (0%)

1.62

-0.03 (-1.82%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-09 2025-05-09/bmo

Earnings (Next)08-12 2025-08-12

Inst Owners6.74%

Inst Owner Change86.2%

Ins Owners7.79%

Ins Owner Change0%

Market Cap126.41M

Analysts80

Price Target14.79 (812.96%)

Short Float %1.48%

Short Ratio1.03

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-118.86%

Min EPS beat(2)-265.02%

Max EPS beat(2)27.3%

EPS beat(4)1

Avg EPS beat(4)-127.99%

Min EPS beat(4)-265.02%

Max EPS beat(4)27.3%

EPS beat(8)3

Avg EPS beat(8)-22.1%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-28.74%

Min Revenue beat(2)-53.66%

Max Revenue beat(2)-3.82%

Revenue beat(4)2

Avg Revenue beat(4)-10.35%

Min Revenue beat(4)-53.66%

Max Revenue beat(4)9.37%

Revenue beat(8)5

Avg Revenue beat(8)31.47%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)3.57%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)-50.79%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)-1.29%

Revenue NY rev (3m)-13.99%

Valuation

		Industry Rank	Sector Rank
PE	40.5
Fwd PE	1.91
P/S	2.12
P/FCF	N/A
P/OCF	N/A
P/B	2.8
P/tB	2.8
EV/EBITDA	18.35

EPS(TTM)0.04

EY2.47%

EPS(NY)0.85

Fwd EY52.37%

FCF(TTM)-0.02

FCFYN/A

OCF(TTM)-0.01

OCFYN/A

SpS0.77

BVpS0.58

TBVpS0.58

PEG (NY)0.04

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	5.29%
ROE	8.64%
ROCE	9.34%
ROIC	7.82%
ROICexc	12.88%
ROICexgc	12.88%
OM	7.74%
PM (TTM)	6.54%
GM	49.97%
FCFM	N/A

ROA(3y)-4.31%

ROA(5y)-11.99%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.72%

GM growth 5Y-7.42%

F-Score4

Asset Turnover0.81

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	0
Cap/Depr	74.55%
Cap/Sales	1.66%
Interest Coverage	6.04
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.49
Quick Ratio	1.69
Altman-Z	-2.94

F-Score4

WACC10.56%

ROIC/WACC0.74

Cap/Depr(3y)84.19%

Cap/Depr(5y)86.74%

Cap/Sales(3y)1.83%

Cap/Sales(5y)2.07%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)0%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%16.67%

EPS Next Y943.67%

EPS Next 2Y431.79%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)0.18%

Revenue growth 3Y11.67%

Revenue growth 5Y-0.48%

Sales Q2Q%169.6%

Revenue Next Year61.73%

Revenue Next 2Y59.52%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-42.59%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y93.16%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y97.42%

OCF growth 3YN/A

OCF growth 5YN/A

PROTALIX BIOTHERAPEUTICS INC (PLX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens